Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells

Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells

<b>Background</b>: The mutation rate of p53 in breast cancer is around 20%. Specific p53 mutations exhibit prion-like abnormal misfolding and aggregation and gain oncogenic function, causing resistance to the chemotherapy drug doxorubicin. In this study, we identified key upstream regula...

Full description

Saved in:
Bibliographic Details
Main Authors: Kuan-Yo Wu, Ana Crucho, Mia Su, Sih-Tong Chen, Chen-Hsiu Hung, Yu-Ling Kou, Yu-Jie Liu, Tzu-Chi Hsu, Fang-Yu Yeh, Ching-Feng Lien, Chia-Chi Chen, Bi-He Cai
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Biomedicines
Subjects:
breast cancer
p53 mutation
aggregation
HSP70 inhibitor
apoptosis
Online Access:https://www.mdpi.com/2227-9059/13/5/1034
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items